Here’s the press launch that has been despatched out immediately
Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCMKTS: JUSHF), a globally-focused, multi-state hashish and hemp operator, introduced that Jushi Europe SA (“Jushi Europe”), a European-based, internationally-focused medical hashish operator, 51%-owned by the Company, was granted a provisional license (the “pre-license”) from INFARMED, I.P., the Portuguese National Authority for Medicines and Health Products (“INFARMED”) via its 100%-owned Portugal-based subsidiary JPTREH Unipessoal Limitada (“Jushi Portugal”).
Jushi Europe was established in March 2020 to develop Jushi’s worldwide growth technique. Jushi Europe is led by Daniel Swasbrook, President of Jushi Europe, who brings over 20 years of worldwide finance expertise, and Jeff Purcell, who joined as Chief Operating Officer of Jushi Europe in March 2020 and was beforehand Senior Vice President at Organigram Holdings.
The pre-license grants conditional approval for Jushi Europe to import, domesticate and export medical hashish from its deliberate greenhouse cultivation facility, which the Company intends to construct close to the City of Beja in southern Portugal (“the Beja facility”).
The Beja facility can be constructed with a ‘closed environment,’ providing the environmental management of indoor cultivation and the solar utilization of outside cultivation, permitting Jushi Europe to sustainably produce high-quality EU-GMP licensed medical hashish. The Company is very centered on environmental sustainability, planning to put in photo voltaic panels on the roof of non-greenhouse areas and a system that removes, collects, treats and recycles water in the air from the dehumidification course of.
Once the ultimate license is granted, Jushi Europe will start exporting EU-GMP medical hashish to licensed international importers, in accordance with INFARMED tips.
Jim Cacioppo, Chief Executive Officer, Chairman and Founder of Jushi, commented, “We see immense potential for medical cannabis in Europe, given the region’s growing acceptance of cannabis for therapeutic use and the early stages of existing medical programs. According to Prohibition Partners’ latest European Cannabis report, countries like Germany are poised to develop multi-billion-dollar markets in the coming years and will rely on imports to supply an increasing demand for medical cannabis. This is our opportunity to enter the market early and become a leading supplier of high-quality medical cannabis products in Europe.”
Daniel Swasbrook, President of Jushi Europe, commented, “We are thrilled to be awarded the pre-license from INFARMED and to start improvement of our sustainable greenhouse manufacturing facility. INFARMED is globally famend for its give attention to high quality assurance and shopper security in the pharmaceutical business, enabling Jushi Europe to function in a regulatory surroundings that aligns with our mandate to produce high-quality, EU GMP medical hashish merchandise to sufferers internationally. “
About Jushi Europe SA
Jushi Europe is a European subsidiary of Jushi Holdings Inc. and is headquartered in Switzerland. Jushi Europe’s technique is concentrated on constructing large-scale manufacturing in Portugal for export to the European medical hashish market. Jushi Europe represents geographic diversification of the Jushi portfolio and an entrance into early-stage hashish markets via long-term investments.